Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy
Clinical trial NCT03777332 · COMPLETED
Trial details
- NCT number
- NCT03777332
- Sponsor
- Apellis Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-05
- Primary completion
- 2021-04-01
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.